There's more unwelcome news for sufferers of genital herpes. Less than a year after Genocea's experimental herpes vaccine went down in flames, Vical's VCL-HB01 met the same fate: no efficacy in Phase II trials. And worse, there's nothing obvious on the horizon that can fill the void.
A group of researchers from Umea University in Sweden published two related studies in their attempt to explore a link between infection